Olaparib

Lynparza

Poly(ADP-Ribose) Polymerase Inhibitor

NADAC/unit N/A

No Shortage Tier 1: 35.9% PA Req: 198.8%

Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic....

Covered Lives

Generic Manufacturers

ASTRAZENECA PHARMACEUTICALS LP

Explore in the Ecosystem

rxsaver.aiCompare prices for Olaparib drfinder.aiFind doctors who prescribe Olaparib rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Olaparib

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.